27.67

3.71% 0.99

After Hours: 27.88 0.21 +0.76%

Adaptive Biotechnologies Corp (ADPT)

Overview News Price History Option Chain Financials Why ADPT Down? Discussions Forecast

Adaptive Biotechnologies Corp stock is traded at $27.67, with a volume of 5.03M. It is up +3.71% in the last 24 hours and up +11.84% over the past month. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Previous Close:

$26.68

Open:

$27.09

24h Volume:

5.03M

Relative Volume:

1.78

Market Cap:

$4.42B

Revenue:

$295.41M

Net Income/Loss:

$-49.64M

P/E Ratio:

-84.51

EPS:

-0.3274

Net Cash Flow:

$-29.54M

1W Performance:

+13.31%

1M Performance:

+11.84%

6M Performance:

+107.73%

1Y Performance:

+114.33%

1-Day Range:

$27.03

$28.72

1-Week Range:

$23.53

$28.72

52-Week Range:

$12.00

$28.72

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Name

Adaptive Biotechnologies Corp

Sector

Healthcare (1066)

Industry

Diagnostics & Research (50)

Phone

206-659-0067

Address

1165 EASTLAKE AVE E, SEATTLE, WA

Employee

624

Twitter

@adaptivebiotech

Next Earnings Date

2026-11-04

Latest SEC Filings

ADPT's Discussions on Twitter

Compare ADPT vs TMO, DHR, NTRA, IQV, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADPT Adaptive Biotechnologies Corp	27.67	3.86B	295.41M	-49.64M	-29.54M	-0.3274
TMO Thermo Fisher Scientific Inc	648.43	225.48B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	208.36	140.70B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	345.34	47.41B	2.50B	-226.32M	71.51M	-1.6412
IQV Iqvia Holdings Inc	268.82	43.09B	16.63B	1.39B	2.12B	8.0674
A Agilent Technologies Inc	153.69	41.42B	7.23B	1.41B	1.09B	4.979

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Resumed	Morgan Stanley	Equal-Weight
Sep-30-25	Initiated	Guggenheim	Buy
Jun-18-25	Initiated	Craig Hallum	Buy
Mar-21-25	Upgrade	Goldman	Neutral → Buy
Jul-05-23	Resumed	JP Morgan	Overweight
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Dec-21-22	Upgrade	Piper Sandler	Neutral → Overweight
Aug-25-22	Initiated	Credit Suisse	Underperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Feb-16-22	Reiterated	BTIG Research	Buy
Feb-16-22	Reiterated	BofA Securities	Buy
Feb-16-22	Reiterated	Goldman	Neutral
Feb-16-22	Reiterated	JP Morgan	Overweight
Oct-15-21	Resumed	Cowen	Outperform
Mar-03-21	Downgrade	Goldman	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Sep-09-20	Initiated	Morgan Stanley	Equal-Weight
Jun-03-20	Initiated	Goldman	Buy
Jul-23-19	Initiated	BTIG Research	Buy
Jul-22-19	Initiated	BofA/Merrill	Buy
Jul-22-19	Initiated	Cowen	Outperform
Jul-22-19	Initiated	Goldman	Neutral
Jul-22-19	Initiated	Guggenheim	Buy
Jul-22-19	Initiated	William Blair	Outperform

View All

Adaptive Biotechnologies Corp Stock (ADPT) Latest News

Sep 04, 2026